1. Home
  2. MDV vs ALXO Comparison

MDV vs ALXO Comparison

Compare MDV & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modiv Industrial Inc. Class C

MDV

Modiv Industrial Inc. Class C

HOLD

Current Price

$17.24

Market Cap

187.5M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.96

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDV
ALXO
Founded
2015
2015
Country
United States
United States
Employees
9
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.5M
205.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MDV
ALXO
Price
$17.24
$1.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$18.00
$3.50
AVG Volume (30 Days)
51.5K
818.2K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
7.50%
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.80
$0.51
52 Week High
$18.96
$2.66

Technical Indicators

Market Signals
Indicator
MDV
ALXO
Relative Strength Index (RSI) 42.12 46.61
Support Level $13.95 $1.56
Resistance Level $18.82 $2.27
Average True Range (ATR) 0.44 0.13
MACD -0.06 -0.03
Stochastic Oscillator 9.80 22.58

Price Performance

Historical Comparison
MDV
ALXO

About MDV Modiv Industrial Inc. Class C

Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: